GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Incyte Corp (MEX:INCY) » Definitions » Cyclically Adjusted FCF per Share

Incyte (MEX:INCY) Cyclically Adjusted FCF per Share : MXN37.09 (As of Mar. 2025)


View and export this data going back to 2019. Start your Free Trial

What is Incyte Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Incyte's adjusted free cash flow per share for the three months ended in Mar. 2025 was MXN27.137. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is MXN37.09 for the trailing ten years ended in Mar. 2025.

During the past 12 months, Incyte's average Cyclically Adjusted FCF Growth Rate was 12.90% per year. During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 42.60% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 65.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Incyte was 175.20% per year. The lowest was -11.60% per year. And the median was 7.30% per year.

As of today (2025-05-28), Incyte's current stock price is MXN1180.69. Incyte's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 was MXN37.09. Incyte's Cyclically Adjusted Price-to-FCF of today is 31.83.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Incyte was 1631.50. The lowest was 36.22. And the median was 102.85.


Incyte Cyclically Adjusted FCF per Share Historical Data

The historical data trend for Incyte's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Incyte Cyclically Adjusted FCF per Share Chart

Incyte Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.17 9.79 20.69 32.43 30.55

Incyte Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 24.06 20.44 24.82 30.55 37.09

Competitive Comparison of Incyte's Cyclically Adjusted FCF per Share

For the Biotechnology subindustry, Incyte's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Incyte's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Incyte's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Incyte's Cyclically Adjusted Price-to-FCF falls into.


;
;

Incyte Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Incyte's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2025 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=27.137/134.9266*134.9266
=27.137

Current CPI (Mar. 2025) = 134.9266.

Incyte Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201506 0.942 100.684 1.262
201509 -0.525 100.392 -0.706
201512 5.227 99.792 7.067
201603 8.219 100.470 11.038
201606 -6.194 101.688 -8.219
201609 7.827 101.861 10.368
201612 8.290 101.863 10.981
201703 -18.766 102.862 -24.616
201706 7.604 103.349 9.927
201709 1.606 104.136 2.081
201712 -10.653 104.011 -13.819
201803 0.708 105.290 0.907
201806 1.974 106.317 2.505
201809 15.099 106.507 19.128
201812 5.323 105.998 6.776
201903 12.279 107.251 15.448
201906 9.333 108.070 11.652
201909 26.036 108.329 32.428
201912 8.832 108.420 10.991
202003 -78.190 108.902 -96.876
202006 23.615 108.767 29.295
202009 13.055 109.815 16.040
202012 5.071 109.897 6.226
202103 14.558 111.754 17.577
202106 9.551 114.631 11.242
202109 20.626 115.734 24.046
202112 7.476 117.630 8.575
202203 17.748 121.301 19.742
202206 14.609 125.017 15.767
202209 24.099 125.227 25.966
202212 22.740 125.222 24.502
202303 -10.588 127.348 -11.218
202306 22.731 128.729 23.825
202309 10.541 129.860 10.952
202312 10.904 129.419 11.368
202403 15.285 131.776 15.650
202406 -52.994 132.554 -53.943
202409 29.478 133.029 29.899
202412 36.687 133.157 37.175
202503 27.137 134.927 27.137

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


Incyte  (MEX:INCY) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Incyte's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=1180.69/37.09
=31.83

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Incyte was 1631.50. The lowest was 36.22. And the median was 102.85.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Incyte Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of Incyte's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Incyte Business Description

Industry
Traded in Other Exchanges
Address
1801 Augustine Cut-Off, Wilmington, DE, USA, 19803
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.